Welcome to our dedicated page for Globus Med news (Ticker: GMED), a resource for investors and traders seeking the latest updates and insights on Globus Med stock.
Globus Medical reports recurring developments in musculoskeletal technology, including sales and earnings updates for its spine, orthopedic and enabling technology businesses. The company develops medical devices, instruments and computer-assisted systems used in musculoskeletal procedures and sells to hospitals, physicians and surgical centers in the United States and international markets.
Company news also covers US Spine demand, Enabling Technologies customer expansion, product pipeline execution, integration activity following completed NuVasive and Nevro transactions, preliminary sales guidance, earnings conference calls and board composition changes.
Globus Medical (NYSE: GMED) announced the acquisition of Durham, NC-based Higgs Boson Health, a digital healthcare experience company incubated out of Duke University. Higgs Boson focuses on AI-driven software to enhance patient and provider experience across the full episode of care.
According to Globus Medical, Higgs Boson’s teams of software developers and AI scientists will join the company to support its vision of a seamless digital healthcare environment. The technology is intended to strengthen Globus Medical’s surgical intelligence pillar by integrating outcomes and analytics along the patient journey, with the stated long-term goal of improving musculoskeletal surgery outcomes.
Globus Medical (NYSE: GMED) reported second quarter 2026 worldwide net sales of $789.6 million, up 5.9% year over year, or 5.6% on a constant currency basis. U.S. net sales grew 3.0%, while international net sales increased 18.0% as reported and 16.2% on a constant currency basis.
GAAP net income was $151.6 million, down 25.3%, with GAAP diluted EPS of $1.10 versus $1.49, mainly due to a prior-year $110.5 million bargain purchase gain from the Nevro acquisition. Non-GAAP diluted EPS was $1.34, up 55.8%. Management cited approximately 200 basis points of adjusted gross margin expansion and record second quarter non-GAAP net income. The company reaffirmed full-year 2026 revenue guidance of $3.18–$3.22 billion and raised non-GAAP diluted EPS guidance to $4.95–$5.05 from $4.70–$4.80.
Globus Medical (NYSE:GMED) plans to release its financial results for the second quarter ended June 30, 2026 after market close on Thursday, August 6, 2026. The earnings release will be posted on the company’s investor website. A teleconference to discuss the results with the investment community will follow at 4:30 p.m. Eastern Time, accessible via live webcast and pre-registered telephone access, with an audio archive available afterward on the Investors page.
Globus Medical (NYSE: GMED) reported Q1 2026 results: worldwide net sales $759.9M (+27.0%; +25.5% constant currency) and GAAP net income $124.3M. GAAP diluted EPS was $0.90 and non-GAAP diluted EPS was $1.12. The company reaffirmed 2026 revenue guide of $3.18B–$3.22B and raised non-GAAP EPS guidance to $4.70–$4.80. Management cited organic growth, Nevro acquisition contribution, margin expansion from operating leverage, and integration progress.
Globus Medical (NYSE:GMED) will announce first quarter results for the period ended March 31, 2026 after market close on Thursday, May 7, 2026.
The company will host a teleconference at 4:30 p.m. Eastern Time the same day, available via live webcast on the Globus Medical Investors page; telephone participation requires advance registration. An audio archive will be posted afterward.
Globus Medical (NYSE:GMED) announced that Director John A. DeFord, PhD stepped down from the Board effective March 23, 2026, and will not seek re-election at the Annual Meeting on June 3, 2026.
The company highlighted Dr. DeFord's contributions during the merger with NuVasive and his service on the Nominating and Governance Committee. The chairman thanked him for his service, and Dr. DeFord expressed appreciation for serving during the company's growth in musculoskeletal technology.
Globus Medical (NYSE: GMED) reported strong Q4 and full‑year 2025 results with Q4 net sales $826.4M (+25.7% as‑reported) and FY2025 net sales $2,938.9M (+16.7%). GAAP diluted EPS was $1.03 in Q4 and $3.92 for FY2025; non‑GAAP diluted EPS was $1.28 Q4 and $3.98 FY2025.
The company cited integration benefits from Nevro and NuVasive, margin expansion, and reaffirmed 2026 revenue guidance of $3.18–$3.22B while updating non‑GAAP EPS guidance to $4.40–$4.50.
Globus Medical (NYSE:GMED) will announce fourth-quarter and full-year 2025 financial results after market close on February 24, 2026. The company will host a teleconference and live webcast at 4:30 p.m. Eastern Time the same day.
Investors can access the live webcast and audio archive on the Globus Medical Investors page. Telephone participation requires advance registration to receive a dial-in number, unique passcode, and registrant ID.
Globus Medical (NYSE: GMED) reported preliminary unaudited sales for Q4 and full year 2025. Q4 2025 sales are estimated at $823.2M, up 25.2% year-over-year on an as-reported basis. Full year 2025 sales are estimated at $2.936B, up 16.5% year-over-year. Excluding Nevro, Globus base business Q4 revenue was $723.3M, up 10.0% year-over-year, led by US Spine. The company issued 2026 revenue guidance of $3.18B–$3.22B and non-GAAP EPS guidance of $4.30–$4.40. Final audited results are expected on Feb 24, 2026.
Globus Medical (NYSE: GMED) reported third quarter 2025 results: worldwide net sales $769.0M (+22.9% / +22.3% constant currency) and GAAP net income $119.0M (+129.5%). GAAP diluted EPS was $0.88 and non-GAAP diluted EPS was $1.18 (+42.6%).
Quarter highlights include U.S. sales +24.6%, international sales +16.5% (13.5% CC), record non-GAAP free cash flow $213.9M (up 24% QoQ), net cash from operations $249.7M, and $40M of share repurchases in Q3 (total repurchases $255.5M YTD).
The company raised 2025 guidance to $2.86–$2.90B revenue and $3.75–$3.85 non-GAAP EPS; Nevro is expected to be accretive in 2025.